FDA clears updated Covid vaccines tailored to XFG variant for seniors and at-risk groups
TL;DR Summary
The FDA approved updated Covid-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi to target the dominant XFG variant, with age approvals varying by manufacturer (65+ and younger people with high-risk conditions; Moderna for children >6 months, Pfizer for 5+, Novavax-Sanofi for 12+). Vaccines can begin shipping for the 2026-27 season, but recommendations will depend on individual risk rather than universal rollout, and the lack of a functioning CDC vaccine advisory panel raises questions about future guidance and insurer coverage. Current Covid activity is low but rising in wastewater/testing data.
- FDA approves updated Covid-19 vaccines for dominant XFG variant The Guardian
- What to Know About New Covid Vaccines for Fall 2026 The New York Times
- FDA just approved updated covid shots. Here’s what to know as cases rise. The Washington Post
- FDA approves updated COVID-19 vaccines from Pfizer & Moderna, companies say KATU
- FDA approves updated Covid-19 vaccines CNN
Reading Insights
Total Reads
0
Unique Readers
21
Time Saved
1 min
vs 2 min read
Condensed
69%
284 → 88 words
Want the full story? Read the original article
Read on The Guardian